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1 Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, 
Copenhagen, Denmark, 2 Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, 
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Background: The incidence of thyroid cancer (TC) is increasing although explanatory 
causes are lacking. A link between cancer and inflammation is well documented but 
unclear for autoimmune thyroid diseases and TC. We aimed to systematically review 
the association between Hashimoto’s thyroiditis (HT) and papillary, follicular, medullary, 
anaplastic thyroid carcinoma, and thyroid lymphoma (TL).
Methods: PubMed, OVID Medline, Google Scholar, and the Cochrane Library were 
searched from 1955 to 2016. The inclusion criteria were age >18 years, ≥20 cases of 
HT or TC. We collectively examined the incidence of HT in TC and of TC in HT.
results: We identified 36 studies (64,628 subjects) published between 1955 and 2016 
from 13 countries. We found a relative risk (RR) of HT among papillary thyroid cancer 
(PTC) of 2.36 [95% confidence intervals (CIs) 1.55–3.29, p <  0.001], an RR of PTC 
among HT of 1.40 (95% CI 1.07–1.85, p = 0.016), and an RR of TL among HT of 9.74 
(95% CI 3.93–24.13, p < 0.001).
conclusion: We report an association between HT and PTC and between HT and TL. 
No association was found between HT and follicular, medullary, or anaplastic thyroid 
cancer.
Keywords: hashimoto’s thyroiditis, autoimmune thyroid disease, thyroid cancer, autoimmune thyroiditis, 
hashimoto’s disease
inTrODUcTiOn
Thyroid cancer (TC) is the most common endocrine malignancy, and the incidence has 
been increasing worldwide during the last decades (1–5). Papillary thyroid carcinoma (PTC) 
(70–80% of all TCs), follicular thyroid carcinoma (FTC) (10–20% of all TCs), medullary thyroid 
carcinoma (MTC) (5–8% of all TCs), and anaplastic thyroid carcinoma (ATC) (<5% of all 
TCs) collectively comprise more than 98% of all thyroid malignancies (6–8). PTC and FTC 
are well-differentiated TCs and generally have a favorable prognosis (7), contrary to MTC and 
ATC with poor prognosis. Thyroid lymphoma (TL) is a rare TC, accounting for 1–5% of all 
thyroid malignancies (9).
Hashimoto’s thyroiditis (HT), e.g., chronic lymphocytic or autoimmune thyroiditis, is a chronic 
inflammation of the thyroid gland, the most common inflammatory thyroid disease, and the typical 
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cause of hypothyroidism (8, 10, 11). Several diagnostic methods 
are used to define HT including ultrasonography-guided fine 
needle aspiration cytology (FNAC), thyroid autoantibodies, 
and surgical material (12), and studies correspondingly include 
HT patients based on different criteria posing a challenge for 
comparison.
A link between cancer and inflammation is well recognized. 
As early as 1863, Rudolf Virchow noted leukocytes in neoplastic 
tissue and suggested a correlation to the development of cancer 
(13, 14). The association between HT and PTC was first described 
by Dailey et al. in 1955 (15), and since then, conflicting results 
have been reported regarding the association between HT and 
thyroid malignancies.
Few systematic reports are published examining the associa-
tion between HT and TC, all investigating PTC, and all fail to 
distinguish HT patients from TC patients, which complicate 
comparisons (11, 16, 17). A systematic review and meta-analysis 
examining the association between HT and TCs other than PTC 
and examining the incidences of HT in TC and of TC in HT has 
not been published.
The aim of this systematic review was to examine the associa-
tion between HT and TC.
MaTerials anD MeThODs
systematic literature search and 
eligibility criteria
This systematic review and meta-analysis was conducted with ref-
erence to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis statement (18).
In August 2016, one author (Christina Resende de Paiva) sys-
tematically searched PubMed, OVID Medline, Google Scholar, 
and the Cochrane Library. The search strategy was carried out 
using the keywords and MESH terms “Hashimoto Disease” OR 
“Hashimoto Thyroiditis” OR “Chronic Lymphocytic Thyroiditis” 
AND “Thyroid Neoplasms” OR “Thyroid Cancer” OR “Thyroid 
Malignancy.”
We included both retrospective and prospective studies that 
examined the relationship between HT and any of the following 
TCs: PTC, FTC, MTC, ATC, and TL. The inclusion criteria were 
restricted to English or Portuguese language, published between 
January 1, 1955 and August 30, 2016, age >18 years and ≥20 cases 
of HT or TC.
We excluded case studies, review articles, articles only provid-
ing data about TC in general as opposed to a subtype of TC, and 
articles that did not include data about all cancer cases (i.e., only 
examining microcarcinomas).
Data extraction, synthesis, and statistical 
analysis
The following information was recorded by one author (Christina 
Resende de Paiva): author, gender distribution, age, year of publi-
cation, country, study design, methods of diagnosis, sample size, 
type of cancer, and number of cancer and HT cases. Included 
studies were categorized into two groups: one group examining 
HT in TC and another examining TC in HT.
Statistics were carried out using MedCalc statistical software 
version 16.8.4. For analysis, we calculated the relative risks (RRs), 
the 95% confidence intervals (CIs), and the pooled effects. A p 
value below 0.05 was considered significant.
resUlTs
The literature search yielded a total of 550 records. From these, we 
manually selected 57 articles for full-text assessment, of which 31 
articles were excluded. Accordingly, 26 studies were left eligible 
for inclusion, and additional 10 studies were identified through 
reference lists yielding a total of 36 records (n = 64,628 subjects) 
(Figure  1; Tables  2 and 3). Nineteen studies (n  =  23,848) 
examined HT among TC (Table 2), and 19 studies (n = 41,643) 
examined TC among HT (Table 3). Of these, 863 patients were 
included in both analyses (19).
In the pooled analysis, most patients were females (n = 8,828, 
82.1%). The median age among patients with TC and HT was 
45.9 years while 47 years among patients with TC without HT. 
Seventeen studies (n = 37,556 subjects) were European, Canadian, 
or US based, 15 studies (n = 25,261 subjects) were Asian, and 4 
studies (n = 1,811 subjects) were Brazilian.
hT in Tc
The HT in TC group included 19 studies (n = 23,848) published 
between 1998 and 2016. Eight studies had a group of patients 
useful as control group enabling us to calculate a RR while 11 
studies did not supply data for this purpose. All studies in this 
group examined material from thyroidectomies (Table 2).
In the pooled analysis, most patients were women (n = 8,050, 
82.4%). The median age for patients with TC and HT was 
45.1 years while it was 46.7 years among patients with TC without 
HT. Four studies (n = 787 subjects) were European, Canadian, 
or US based, 11 studies (n = 21,250 subjects) were Asian, and 4 
studies (n = 1,811 subjects) were Brazilian.
HT in PTC
Among patients with PTC (n  =  11,155), 18.90% had HT 
(n = 2,108) (16, 19–29, 31–36). The female:male (F:M) ratio was 
4.8:1 (7,815:1,623) for PTC patients, and the RR of having HT in 
PTC patients varied from 0.60 (95% CI 0.29–1.21) to 23.97 (95% 
CI 6.98–82.29). With 915 HT cases among 4,725 PTC patients 
and a control group of 894 HT cases among 10,862 patients 
without cancer (non-TC), the pooled effect of the RRs was 2.26 
(95% CI 1.55–3.29, p < 0.001) (Figure 2).
An association was found between HT and PTC.
HT in FTC
Among patients with FTC (n = 363), 4.68% had HT (n = 17) (16, 
19, 25, 27, 29). The F:M ratio was 2.5:1 (226:89) for FTC patients, 
and the RR of having HT in FTC patients varied from 0.18 (95% 
CI 0.012–2.85) to 1.0 (95% CI 0.40–2.49). With 5 HT cases among 
79 FTC patients and a control group of 91 HT cases among 932 
non-TC patients, the pooled effect of the RRs was 0.66 (95% CI 
0.14–3.13, p = 0.599).
No association was found between HT and FTC.
FigUre 1 | Preferred reporting items for systematic reviews and Meta-analysis flow diagram of article selection. HT, Hashimoto’s thyroiditis; TC, 
thyroid cancer.
TaBle 1 | Overview of the associations between hT and Tc.
PTc FTc MTc aTc Tl
HT in TC group HT Associated (p < 0.001) Not associated (p = 0.599) Not associated (p = 0.18) N/A N/A
TC in HT group HT Associated (p = 0.016) Not associated (p = 0.915) Not associated (p = 0.07) Not associated (p = 0.499) Associated (p < 0.001)
N/A, not available; HT, Hashimoto’s thyroiditis; TC, thyroid cancer; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; MTC, medullary thyroid cancer; ATC, anaplastic 
thyroid cancer; TL, thyroid lymphoma.
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HT in MTC
One study (n = 863 subjects) examined the association between 
HT and MTC (19). Among patients with MTC (n = 15), 20% had 
HT (n = 3) with a RR of 2.04 (95% CI 0.72–5.75). The F:M ratio 
was 1.5:1 (9:6).
No association was found between HT and MTC.
HT in ATC
No studies examined this association.
HT in TL
Two studies examined the association between HT and TL, but 
none of them had a control group of HT cases among non-TC 
patients (16, 30). Therefore, the RR could not be calculated. 
Nevertheless, 35.14% of patients with TL (n  =  37) had HT 
(n = 13). There were no data on the F:M ratio.
Tc in hT
The TC in HT group included 19 studies (n = 41,643) published 
between 1955 and 2015. Thirteen studies had a control group, 
and six studies did not supply data for this purpose. Fifteen stud-
ies examined material from thyroidectomies while four studies 
examined FNAC material (Table 3).
In the pooled analysis, most patients were women (n = 778, 
78.7%). The median age among patients with TC and HT was 46.6 
and 47.2 years among patients with TC without HT. Five studies 
(n = 19,898 subjects) were European, nine studies (n = 16,871 
subjects) were US based, and four studies (n =  4,874 subjects) 
were Asian.
PTC in HT
Among patients with HT (n = 7,873), 9.03% had PTC (n = 711) 
(15, 19, 24, 37–52). Six studies reported the F:M ratio among 
patients with PTC to be 3.9:1 (732:190). The RR of having PTC 
in HT patients varied from 0.35 (95% CI 0.08–1.50) to 3.1 (95% 
CI 2.61–3.78). With 601 PTC cases among 5,312 HT patients 
and a control group of 2,236 PTC cases among 31,708 non-HT 
patients, the pooled effect of the RRs was 1.40 (95% CI 1.07–1.85, 
p = 0.016) (Figure 2).
An association was found between PTC and HT.
TaBle 2 | studies examining the incidence of hT in Tc.
reference country study type study method sample 
size
Type of cancer Tc 
cases 
(n)
hT 
cases 
(n)
Tc cases 
(F:M)
Tc + hT 
(age, 
median)
Tc ÷ hT 
(age, 
median)
% hT in Tc (hT/Tc) % hT in non-
Tc (hT/non-
Tc) (control 
group)
relative 
risk
95% ci
(20) Brazil Retrospective Thyroidectomy 49 Papillary 33 14 30:3 48.5 43.2 27.27 (9/33) 31.25 (5/16) 0.87 0.35–2.18
(21) China Retrospective Thyroidectomy 619 Papillary 619 222 484:135 45.9 45.5 35.86 (222/619) N/A N/A N/A
(22) Brazil Retrospective Thyroidectomy 315 Papillary 41 14 34:7 44.9 49.1 26.83 (11/41) 1.12 (3/268) 23.97 6.98–82.29
(23) China Retrospective Thyroidectomy 2,052 Papillary 1,004 254 828:176 N/A N/A 18.63 (187/1,004) 6.42 
(66/1,028)
2.90 2.22–3.79
(24) Italy Retrospective Thyroidectomy 178 Papillary 71 27 68:21 N/A N/A 26.76 (19/71) 8.99 (8/89) 2.98 1.39–6.40
(25) Korea Retrospective Thyroidectomy 1,329 Papillary 1,028 336 821:207 47.5 48 29.86 (307/1,028) 9.64 (24/249) 3.10 2.09–4.58
Follicular 52 32:20 9.62 (5/52) 1.00 0.40–2.49
(26) Korea Retrospective Thyroidectomy 303 Papillary 269 60 225:44 42.8 48.3 21.56 (58/269) N/A N/A N/A
(27) China Retrospective Thyroidectomy 1,997 Papillary 1,788 93 1,450:338 39.9 40.8 4.75 (85/1,788) N/A N/A N/A
Follicular 209 153:56 3.83 (8/209)
(28) China Retrospective Thyroidectomy 2,478 Papillary 676 256 538:138 41.3 44.8 18.79 (127/676) 7.16 
(129/1,802)
2.624 2.09–3.30
(29) Brazil Retrospective Thyroidectomy 1,395 Papillary 93 74 81:12 N/A N/A 18.28 (17/93) N/A N/A N/A
Follicular 27 23:4 11.11 (3/27)
(19) Jordan Retrospective Thyroidectomy 863 Medullary 15 78 9:6 51.3 49.9 20 (3/15) 9.81 (67/683) 2.04 0.72–5.75
Papillary 137 102:35 5.84 (8/137) 0.60 0.29–1.21
Follicular 27 18:9 0 (0/27) 0.18 0.01–2.85
(30) Canada Retrospective Thyroidectomy 20 Lymphoma 20 12 N/A N/A N/A 60 (12/20) N/A N/A N/A
(16) USA Retrospective Thyroidectomy 453 Papillary 388 59 267:121 41 43 14.69 (57/388) N/A N/A N/A
Follicular 48 N/A 2.08 (1/48)
Lymphoma 17 N/A 5.88 (1/17)
(31) China Retrospective Thyroidectomy 8,524 Papillary 1,735 839 N/A 43.1 46.6 14.24 (247/1,735) 8.80 
(592/6,727)
1.62 1.41–1.86
(32) Brazil Retrospective Thyroidectomy 52 Papillary 52 17 48:4 51.3 43.1 32.69 (17/52) N/A N/A N/A
(33) Korea Retrospective Thyroidectomy 1,357 Papillary 1,357 359 1,176:181 44.5 45.9 26.46 (359/1,357) N/A N/A N/A
(34) Japan Retrospective Thyroidectomy 1,533 Papillary 1,533 281 1,402:131 42.6 48.6 18.33 (281/1,533) N/A N/A N/A
(35) USA Retrospective Thyroidectomy 136 Papillary 136 41 95:41 45.5 54 30.15 (41/136) N/A N/A N/A
(36) Korea Retrospective Thyroidectomy 195 Papillary 195 56 166:29 45.9 49.6 28.72 (56/195) N/A N/A N/A
N/A, not available; TC, thyroid cancer; HT, Hashimoto’s thyroiditis; F, female; M, male; CI, confidence interval.
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TaBle 3 | studies examining the incidence of Tc in hT.
reference country study type study method sample 
size
Type of cancer Tc 
cases 
(n)
hT 
cases 
(n)
Tc 
cases 
(F:M)
Tc + hT 
(age, 
median)
Tc ÷ hT 
(age, 
median)
% Tc in hT (Tc/hT) % Tc in non-hT (Tc/
non-hT) (control 
group)
relative 
risk
95% ci
(37) USA Retrospective Thyroidectomy 1,198 Papillary 292 217 215:77 N/A N/A 29.03 (63/217) 23.34 (229/981) 1.24 0.98–1.58
(38) USA Retrospective Thyroidectomy 2,718 Papillary 807 567 N/A N/A N/A 42.68 (242/567) 26.27 (565/2,151) 1.63 1.44–1.83
Follicular 56 1.76 (10/567) 2.14 (46/2,151) 0.83 0.42–1.62
(39) Turkey Prospective Fine needle 
aspiration 
cytology (FNAC)
715 Papillary 21 164 N/A N/A N/A 1.22 (2/164) 3.45 (19/551) 0.35 0.08–1.50
(24) Italy Retrospective Thyroidectomy 47 Papillary 13 47 12:1 45.7 N/A 27.66 (13/47) N/A N/A N/A
(40) Poland Retrospective Thyroidectomy 7,545 Papillary 636 452 N/A 53.5 52.3 23.45 (106/452) 7.47 (530/7,093) 3.14 2.61–3.78
(41) Japan Retrospective FNAC 2,036 Papillary 36 2,036 N/A N/A N/A 1.77 (36/2,036) N/A N/A N/A
Lymphoma 2 0.10 (2/2,036)
(42) Croatia Retrospective FNAC 10,508 Papillary 269 2,156 236:33 50 51 1.95 (42/2,156) 2.72 (227/8,352) 0.72 0.58–0.99
(15) USA Prospective Thyroidectomy 2,336 Papillary 29 278 N/A 37.5 36 10.43 (29/278) N/A N/A N/A
(43) USA Retrospective Thyroidectomy 8,850 Papillary 141 432 N/A N/A N/A 1.85 (8/432) 1.58 (133/8,418) 1.17 0.58–2.38
Follicular 173 0.93 (4/432) 2.01 (169/8,418) 0.46 0.17–1.24
Lymphoma 16 1.16 (5/432) 0.13 (11/8,418) 8.86 3.09–25.38
(44) USA Retrospective Thyroidectomy 812 Papillary 179 98 142:37 41 39 34.7 (34/98) 20.4 (145/710) 1.699 1.25–2.31
Follicular 21 16:5 9.2 (9/98) 1.69 (12/710) 5.434 2.35–12.56
Anaplastic 3 3:0 1.02 (1/98) 0.28 (2/710) 3.622 0.33–39.58
(19) Jordan Retrospective Thyroidectomy 863 Medullary 15 78 9:6 51.3 49.9 3.85 (3/78) 1.53 (12/785) 2.516 0.73–8.73
Papillary 137 102:35 10.26 (8/78) 16.43 (129/785) 0.624 0.32–1.23
Follicular 27 18:9 0 (0/78) 3.44 (27/785) 0.181 0.01–2.94
(45) Turkey Retrospective Thyroidectomy 613 Papillary 171 92 N/A 43 46.5 43.48 (40/92) 25.14 (131/521) 1.729 1.31–2.28
Follicular 11 N/A 1.09 (1/92) 1.92 (10/521) 0.566 0.07–4.37
Medullary 5 N/A 0 (0/92) 0.96 (5/521) 0.510 0.03–9.15
Lymphoma 1 N/A 1.09 (1/92) 0 (0/521) 16.839 0.69–410.24
(46) Greece Retrospective Thyroidectomy 140 Papillary 32 42 25:7 49.3 54.7 28.57 (12/42) 20.41 (20/98) 1.400 0.76–2.60
(47) USA Retrospective Thyroidectomy 48 Papillary 6 48 N/A 51.7 N/A 12.5 (6/48) N/A N/A N/A
(48) USA Retrospective Thyroidectomy 60 Papillary 2 60 N/A N/A N/A 3.33 (2/60) N/A N/A N/A
(49) USA Retrospective Thyroidectomy 92 Papillary 24 92 N/A N/A N/A 26.09 (24/92) N/A N/A N/A
Follicular 4 4.35 (4/92)
Medullary 1 1.09 (1/92)
(50) USA Retrospective Thyroidectomy 757 Papillary 16 77 N/A N/A N/A 2.60 (2/77) 2.06 (14/680) 1.262 0.29–5.45
(Continued )
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FTC in HT
Among patients with HT (n = 2,296), 1.26% had FTC (n = 29) 
(19, 38, 43–45, 49, 51, 52). Two studies reported the F:M ratio 
among patients with FTC to be 2.4:1 (34:14). The RR of having 
FTC in HT patients varied from 0.18 (95% CI 0.01–2.94) to 
5.43 (95% CI 2.35–12.56). With 25 FTC cases among 2,204 HT 
patients and a control group of 267 FTC cases among 13,953 
non-HT patients, the pooled effect of the RRs was 0.95 (95% CI 
0.35–2.57, p = 0.915).
No association was found between FTC and HT.
MTC in HT
Among patients with HT (n = 370), 1.62% had MTC (n = 6) (19, 
45, 49, 51). One study reported the F:M ratio among patients with 
MTC as 1.5:1 (9:6). The RR of having MTC in HT patients varied 
from 0.51 (95% CI 0.029–9.15) to 4.99 (95% CI 0.71–35.05). With 
5 MTC cases among 278 HT patients and a control group of 19 
MTC cases among 1,845 non-HT patients, the poled effect of the 
RRs was 2.49 (95% CI 0.93–6.67, p = 0.07).
No association was found between MTC and HT.
ATC in HT
Among patients with HT (n = 206), 0.49% had ATC (n = 1) (44, 
51). One study reported the F:M ratio among patients with ATC 
as 3:0. The RR of having ATC in HT patients varied from 0.71 
(95% CI 0.04–13.60) to 3.62 (95% CI 0.33–39.58). With one ATC 
case among 206 HT patients and a control group of five ATC cases 
among 1,249 non-HT patients, the pooled effect of the RRs was 
1.90 (95% CI 0.30–12.19, p = 0.499).
No association was found between ATC and HT.
TL in HT
Among patients with HT (n = 3,497), 0.37% had TL (n = 13) 
(41, 43, 45, 51, 52). No studies reported the F:M ratio among 
patients with TL. The RR of having TL in HT patients varied 
from 8.86 (95% CI 3.09–25.38) to 16.84 (95% CI 0.69–410.24). 
With 11 cases of TL among 1,461 HT patients and a control 
group of 11 cases of TL among 10,307 non-HT patients, the 
pooled effect of the RRs was 9.74 (95% CI 3.93–24.13, p < 0.001) 
(Figure 2).
An association was found between TL and HT.
We observe an association between HT and PTC among both 
patient groups and a corresponding association between HT and 
TL among HT patients. No association was found between HT 
and FTC or MTC in both groups of patients neither an asso-
ciation between HT and ATC among HT patients (Table 1). The 
remaining associations could not be evaluated due to lack of data. 
In all subtypes of TC, females were more often affected than males 
with F:M ratios ranging from 1.5:1 to 4.8:1.
DiscUssiOn
To our knowledge, we present the first systematic review on the 
association between HT and five types of TC, and the largest 
review on HT and PTC examining both HT and TC patient 
groups. Based on 64,628 subjects, we report a correlation between 
BA
0,1 1 10 100 1000
Relative risk
Chesky, 1962
Gul, 2010
Yi Zhang, 2014
Holm, 1985
Total (fixed effects)
Total (random effects)
FigUre 2 | relative risk (rr) of hashimoto’s thyroiditis (hT) in thyroid cancers (Tcs) and of Tcs in hT. (a) RR of HT in patients with papillary thyroid 
cancer (PTC) (left) and of PTC in patients with HT (right). (B) RR of thyroid lymphoma in patients with HT.
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stimulate follicular epithelial proliferation (64). McLeod et  al. 
conducted a systematic review reporting that elevated TSH levels 
are associated with an increased risk of TC (65). Similar studies 
have also reported that elevated TSH values are associated with a 
more advanced stage of TC (66–69) and that treatment with l-T4, 
by reducing TSH levels, decreases the risk of TC (70). However, 
these findings are almost exclusively based on patients with PTC 
and might not be applicable to other subtypes of TC.
Biomolecular markers have been identified as possibly being 
involved in neoplastic transformation from HT to TC. These 
include RET/PTC rearrangements, p63 protein expression, 
BRAF mutation, and PI3K/Akt expression (71–73). For instance, 
p63 is commonly expressed in HT and in PTC where as there is 
no such expression in normal thyroid tissue (71). Again, such 
mechanisms have almost exclusively been investigated in PTC. 
Thus, we know very little about other subtypes of TC and what 
might induce their development.
Studies examining the relationship between HT and TC 
through FNAC tend not to show a higher risk of TC (11). This 
raises the question of the sensitivity of FNAC and whether FNAC 
is adequate for monitoring HT. On the other hand, thyroidec-
tomy might identify subclinical TCs that are unlikely to impact 
overall survival. It has been reported that the chance of finding an 
incidental papillary carcinoma at autopsy ranges from 3 to 36% 
(74). Either way, the diagnostic method seems to affect whether 
an association between HT and TC is found or not and this fact 
should be considered since most studies included in our analysis 
are based on thyroidectomies.
HT and PTC among both HT and TC patients and between HT 
and TL among HT patients. We found no association between HT 
and FTC or MTC among these patient groups and no association 
between HT and ATC among HT patients.
The annual incidence of HT is estimated to be 0.3–1.5 cases 
per 1,000 persons worldwide affecting up to 2% of any general 
population (53). Thus, our findings impact a large fraction of the 
global population, and clinicians should consider the higher risk 
of TC in patients with HT and might consider wider indications 
for a workup when this patient group presents suspect symptoms 
of cancer.
It has been proposed that PTC in the setting of HT is associ-
ated with a better prognosis, which might be explained by earlier 
discovery since most HT patients receive more frequent medical 
checkups for their hypothyroidism (27, 34, 54).
The incidence of TC is increasing, primarily due to papillary 
microcarcinomas (≤10  mm) (55, 56) possibly due to changes 
in immigration, diagnostic criteria or surgical interventions 
of benign thyroid disease as well as increased diagnostic activ-
ity, improved diagnostic tools and coincidentally identified 
microcarcinomas (1). Some countries have introduced iodized 
salt programs and have since observed increasing trends of TC 
(1,  57–62), while other countries have not introduced these 
programs or observed a decrease in iodine intake although the 
incidence of TC continues to increase here as well (3, 63).
Malignant transformation in the thyroid gland might be 
caused by cellular mediators produced by immune cells in states 
of chronic inflammation (14), or by elevated levels of TSH that 
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Very few studies have investigated the association between 
HT and TCs other than PTC and the mechanisms that might 
explain such associations. Therefore, the number of patients 
with TCs other than PTC included in our study is also limited 
compared to patients with PTC. This affects the strength of the 
statistical analysis regarding these subtypes of TC, primarily 
MTC and ATC.
In general, several aspects should be considered regarding 
bias, in particular selection bias. Studies examining associations 
between HT and TC are very heterogeneous in terms of diagnos-
tic methods for HT challenging valid evaluations, and statistical 
strength also varies considerably among studies. Furthermore, 
few studies have available data on when HT was diagnosed, 
i.e., if patients had HT prior to the diagnosis of TC, or if the 
diseases were diagnosed simultaneously. This makes it difficult 
to determine whether patients have HT prior to their cancer or 
if their cancer might have induced HT. Likewise, time from HT 
diagnosis to development of TC remains unknown for patients 
with prior HT.
Our systematic review found an association between HT and 
PTC among HT and TC patients and between HT and TL among 
HT patients with RRs ranging from 1.4 to 9.7. We should there-
fore consider wider indications for a workup when this patient 
group presents suspect symptoms of cancer. The prognosis of 
these subtypes of TC is favorable, but there is space for further 
improvement and even though our study did not find a correla-
tion between HT and subtypes of TC with poor prognosis, i.e., 
MTC and ATC, studies on this matter are limited and such an 
association might exist after all. Increased awareness of suspect 
symptoms of cancer among patients with HT might therefore 
identify such TCs earlier and thus improve their prognosis as well.
To better understand and validate the association between 
HT and TC and to exclude biases, prospective studies involving 
large cohorts and long-term follow-up are needed. Furthermore, 
uniform diagnostic criteria would strengthen future research.
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